Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLUTION: Durvalumab + Tremelimumab Maintenance in NSCLC
NCT03319316Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Nov 2018; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03319316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319316.